# Sanofi Discontinues Next-Generation Eczema Drug Development

> news · REPORTED · 2026-07-28

Sanofi disclosed it has discontinued development of its next-generation eczema drug candidate after efficacy and safety concerns emerged, highlighting the difficulty of developing a successor to its blockbuster Dupixent franchise. The decision underscores competitive and scientific hurdles in the atopic dermatitis pipeline.

About Sanofi: Sanofi is a global biopharmaceutical company developing and commercializing a broad portfolio of medicines including immunology, rare disease, oncology, and vaccines, with Dupixent as its leading product.

- Company: Sanofi
- Sector: therapeutics
- Primary source: https://afs.lambda-bio.com/blog/top-biotech-news-28-july-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.